The development of lapdap, an affordable new treatment for malaria

Lancet Infectious Diseases

Volumn 3, Issue 3, 2003, Pages 162-168

  Lang, Trudie ^a   Greenwood, Brian ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROGUANIL; CHLORPROGUANIL PLUS DAPSONE; DAPSONE; FANSIDAR; PYRIMETHAMINE; SULFADOXINE; UNCLASSIFIED DRUG;

ANTIMALARIAL ACTIVITY; CLINICAL TRIAL; DEVELOPING COUNTRY; DRUG APPROVAL; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG MECHANISM; DRUG RESEARCH; FINANCE; FINANCIAL MANAGEMENT; GOVERNMENT; HUMAN; MALARIA; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; TOXICITY TESTING; UNITED KINGDOM; WORLD HEALTH ORGANIZATION;

EID: 0037374401     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(03)00547-4     Document Type: Review

References (23)

1. Winstanley PA. Chemotherapy for falciparum malaria: the amoury, the problems and the prospects. Parasitol Today 2000; 16: 146-53.
2. Nzila AM, Nduati E, Mberu EK, et al. Molecular evidence of greater selective pressure for drug resistance exerted by the long-acting antifolate Pyrimethamine/Sulfadoxine compared with the shorter-acting chlorproguanil/dapsone on Kenyan Plasmodium falciparum. J Infect Dis 2000; 181: 2023-28.
3. Ogutu BR, Smoak BL, Nduati RW, et al. The efficacy of pyrimethamine-sulphadoxine (Fansidar R) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children. Trans R Soc Trop Med Hyg 2000; 94: 83-84.
4. Nwanyanwu OC, Ziba C, Macheso A, Kazembe P. Efficacy of sulphadoxine-pyrimethamine for acute uncomplicated malaria due to Plasmodium falciparum in Malawian children under five years old. Trop Med Int Health 2000; 5: 355-58.
5. Trigg JK, Mbwana H, Chambo O, et al. Resistance to pyrimethamine/sulfadoxine in Plasmodium falciparum in 12 villages in north east Tanzania and a test of chlorproguanil/dapsone. Acta Tropica 1997; 63:185-89.
6. Mutabingwa T, Nzila A, Mberu E, et al. Chlorproguanil-dapsone for treatment of drug-resistant falciparum in Tanzania. Lancet 2001; 358: 1218-23.
7. Dorsey G, Njama D, Kamya MR. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 2002; 360: 2031-38.
8. Reich MR. The global drug gap. Science 2001; 287: 1979-81.
9. Webber D, Kremer M. Perspectives on stimulating industrial research and development for neglected infectious diseases. Bull World Health Organ 2001; 79: 735-41.
10. Trouiller P, Olliario P, Torreelec E, et al. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet 2002; 359: 2188-94.
11. Watkins WM, Chulay JD, Sixsmith DG, Spencer HC, Howells RE. A preliminary pharmacokinetic study of the antimalarial drugs, proguanil and chlorproguanil. J Pharm Pharm 1987; 39: 261-65.
12. Winstanley P, Watkins W, Muhia D, et al. Chlorproguanil/dapsone for uncomplicated Plasmodium falciparum malaria in young children: pharmacokinetics and therapeutic range. Trans R Soc Trop Med Hyg 1997; 91: 322-27.
13. Watkins WM, Brandling-Bennett AD, Nevill CG, et al. Chlorproguanil/dapsone for the treatment of non-severe Plasmodium falciparum malaria in Kenya: a pilot study. Trans R Soc Trop Med Hyg 1988; 82: 398-403.
14. Amukoye E, Winstanley PA, Watkins WM, et al. Chlorproguanil-dapsone: effective treatment for uncomplicated falciparum malaria. Antimicrob Agents Chemother 1997; 41: 2261-64.
15. Blockman M, Folbes P, Smith G, Gabriels A. Rising dose tolerance study of chlorproguanil and dapsone in healthy volunteers. Poster presentation. 2nd European Congress on Tropical Medicine; 1995 Sept 14-18; Liverpool, UK.
16. Sulo J, Chimpeni P, Hatcher J, et al. Chlorproguanildapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 2002; 360: 1136-43.
17. Keuter M, van Eijk A, Hoogstrate M, et al. Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega District, Kenya. London: BMJ Publishing, 1990: 466-70.
18. Winstanley PA, Mberu EK, Szwandt ISF, Breckenridge AM, Watkins WM. The in-vitro activity of novel antifolate drug combinations against Plasmodium falciparum and human granulocyte colony-forming-units. Antimicrob Ag Chemother 1995; 39: 948-52.
19. Watkins WM, Mberu EK, Winstanley PA, Plowe C. The efficacy of antifolate combinations in Africa: a predictive model based on pharmacodynamic and pharmacokinetic analyses. Parasitol Today 1997; 13: 459-64.
20. Maxwell CA, Myamba J, Njunwa KJ, Greenwood BM, Curtis CF. Comparison of bednets impregnated with different pyrethroids for their impact on mosquitoes and on re-infection with malaria after clearance of pre-existing infections with chlorproguanil-dapsone. Trans R Soc Trop Med Hyg 1999;93:4-11.
21. Kublin JG, Dzinjalamala FK, Kamwendo DD, et al. Molecular markers for failure ofsulphadoxinepyrimethamine and chlorproguanil-dapsone treatment for Plasmodium falciparum malaria. J Infect Dis 2002; 185: 380-408.
22. White N. Antimalarial drug resistance and combination chemotherapy. Phil Trans R Soc Lond B Biol Sci 1999; 354: 739-49.
23. Anon. The pharmaceutical industry. The Economist, 1998 Feb 21; 1-15.